Free Trial

British American Tobacco (BATSLN; Baa2 Pos, BBB+ S, BBB+ S) {BATS LN Equity}

CONSUMER STAPLES

Nothing new in BAT headlines from its AGM remarks. Worth noting it's aiming for 50% revenue from smokeless products by 2035 vs. PM targeting 67% by 2030 - stark difference on exposure into the high-growth segment might be reflective of the cost of BAT directing cash towards continuous deleveraging. We don't expect S&P to push it on A- on new leverage targets, Moody's upgrade (to Baa1) would be no surprise/priced. Liquidity premium on broader sell-offs remain X-factor; curve still at relative wides post 32s pricing.


  • FY24 guidance unch at low single digit organic growth in revenue and EBIT. Operating cash conversion expected at 90%+. Does warn expected to be 2H skewed with capex higher in 1H & macro pressures & illicit single-use vapes in the US.
  • Medium term guidance is for +3-5% organic revenue growth & mid-single digit adj EBIT growth.
  • Reiterates buybacks started (was minimal - over next 2 years nets ITC sale proceeds/£1.6b) & deleveraging target towards 2-2.5x (current 2.6x).


To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.